Clinical Trials

Other hematologic neoplasmPlasma cell

510 enrolled 1 FDA

Multiple Myeloma, Hematologic Neoplasms

NCT04728893 2026-03-16

MK-1026-003

490 enrolled

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Hematologic Neoplasms

NCT07221500 2026-03-16

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

100 enrolled

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03591510 2026-03-13

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

22 enrolled

Leukemia, Myeloid, Acute

NCT05963074 2026-03-13

TAILOR

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04557098 2026-03-12

MajesTEC-1

194 enrolled 1 FDA

Hematologic Neoplasms

NCT05458297 2026-03-12

MK-2140-006

223 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT02723994 2026-03-11

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

171 enrolled

Burkitt Lymphoma, Leukemia

NCT05537766 2026-03-10

ZUMA-25

19 enrolled 28 charts

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT06456463 2026-03-09

TRILLIUM

83 enrolled

Leukemia, Myeloid, Acute

NCT07033598 2026-03-05

PROSPERA

66 enrolled

Leukemia, Myelomonocytic, Chronic

NCT05479994 2026-03-04

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

100 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06588478 2026-03-02

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

249 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06524375 2026-02-25

BRAVE

118 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06637501 2026-02-23

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

94 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05005442 2026-02-19

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

192 enrolled 22 charts

Hematologic Neoplasms

NCT07271667 2026-02-13

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

108 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04977024 2026-02-11

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

LymphoidOther hematologic neoplasmPlasma cell

63 enrolled

COVID-19, Leukemia, Lymphoma, Multiple Myeloma

NCT05197426 2026-02-11

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

19 enrolled 24 charts

Leukemia, Myeloid, Acute

NCT04895436 2026-02-09

ReVenG

75 enrolled

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04849416 2026-02-06

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

87 enrolled 19 charts

Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05748171 2026-02-03

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

100 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04116437 2026-01-28

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

96 enrolled

Phase 2 Not yet recruiting

Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07024706 2026-01-21

MAVRiC

80 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07162181 2026-01-21

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

13 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04150029 2026-01-13

STIMULUS-AML1

90 enrolled 26 charts

Leukemia, Myeloid, Acute

NCT02337829 2026-01-08

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

48 enrolled 12 charts

Chromosome 17 deletion, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT03874858 2026-01-06

DANTE

124 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT06514794 2026-01-05

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

125 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02966756 2025-12-24

A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

110 enrolled

Chromosome 17 deletion, Leukemia, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07154264 2025-12-24

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

66 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06465433 2025-12-10

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab

25 enrolled

Hematologic Neoplasms

NCT04703192 2025-12-09

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

155 enrolled 11 charts

Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06824168 2025-12-04

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

130 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT06539182 2025-12-01

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

155 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03578367 2025-11-10

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

104 enrolled 11 charts

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04496349 2025-11-04

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

78 enrolled

Phase 2 Enrolling by invitation

Lymphoma, Non-Hodgkin, Leukemia, Prolymphocytic, T-Cell

NCT04093570 2025-10-31

A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

332 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04511130 2025-10-30

ARTEMIS

92 enrolled

Leukemia, Myeloid, Acute

NCT04266795 2025-10-21

PEVENAZA

164 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT05105841 2025-10-15

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

20 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05384587 2025-10-14

ASC2ESCALATE

34 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT05358808 2025-09-30

ACHIEVE

16 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06514534 2025-09-22

ASC4TARGET

20 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06384261 2025-09-10

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

120 enrolled

Leukemia, Myeloid, Acute

NCT03860844 2025-09-09

ISAKIDS

67 enrolled 25 charts